North East and North Cumbria
ICS Formulary
ICS Formulary
4 Central nervous system
04-01-01 Daridorexant
| Daridorexant Quviviq® |
|
Formulary
|
|
 NICE TA922: Daridorexant for treating long-term insomnia |
|
Links
- Clinical Commissioning Policy: Sodium oxybate for symptom control of narcolepsy with cataplexy (children and adolescents aged 7 until 19 years)
MELATONIN – Information for Primary Care (2018)- MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs
- MHRA Drug Safety Update (May 2014): Zolpidem: risk of drowsiness and reduced driving ability
- MHRA Drug Safety Update (Oct 2021): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
- MHRA Drug Safety Update (Oct 2021): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
NENC Palliative and End of Life Care Symptom Control Guidelines- NICE NG62: Cerebral palsy in under 25s: assessment and management
- NICE TA77: Insomnia - newer hypnotic drugs
- NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
- NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
- NICE TA922: Daridorexant for treating long-term insomnia
- North of Tyne, Gateshead and North Cumbria - Melatonin Deprescribing Guideline (March 2022)
- North of Tyne, Gateshead and North Cumbria - Melatonin for the management of Sleep – Wake Disorders in Children and Young People
- NTAG - Treatment Appraisal Decision Summary - Sodium Oxybate
- Tees, Esk and Wear - Melatonin Shared Care Guideline
- TEWV - Medicines Optimisation – Interactive Guide
- TEWV Guidelines
- TEWV Safe Transfer of Prescribing Guidance